Vanda Pharmaceuticals (VNDA) : Traders are bullish on Vanda Pharmaceuticals (VNDA) as it has outperformed the S&P 500 by a wide margin of 12.42% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.25%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.31% in the last 1 week, and is up 13.58% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 9.21% and the 50-Day Moving Average is 12.57%. Vanda Pharmaceuticals (NASDAQ:VNDA): On Fridays trading session , Opening price of the stock was $12.98 with an intraday high of $13.15. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $12.63. However, the stock managed to close at $12.8, a loss of 1.23% for the day. On the previous day, the stock had closed at $12.96. The total traded volume of the day was 534,017 shares.
The company Insiders own 8.45% of Vanda Pharmaceuticals shares according to the proxy statements. Institutional Investors own 94.13% of Vanda Pharmaceuticals shares.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.